CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2199-2206

  Hernández, Luis ^a   Beà, Silvia ^a   Pinyol, Magda ^a   Ott, German ^b   Katzenberger, Tiemo ^b   Rosenwald, Andreas ^b   Bosch, Francesc ^a   López Guillermo, Armando ^a   Delabie, Jan ^c   Colomer, Dolors ^a   Montserrat, Emili ^a   Campo, Elías ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; MESSENGER RNA; PROTEIN P53;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE 4 GENE; DISEASE ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE NUMBER; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MANTLE CELL LYMPHOMA; MOUSE DOUBLE MINUTE 2 GENE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 20144389458     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1526     Document Type: Article

References (51)

1. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2726-32.
2. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996;87:3351-9.
3. Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997;89:272-80.
4. Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996;87:4302-10.
5. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97.
6. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001;61:2409-12.
7. Dreyling MH, Bullinger L, Ott G, et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 1997;57:4608-14.
8. 1 cyclins. Cell 1992;71:323-34.
9. 1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 1994;14:2077-86.
10. Sherr CJ. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
11. Miliani De Marval PL, Macias E, Conti CJ, Rodriguez-Puebla ML. Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 2003;11:1863-73.
12. Rao RN, Stamm NB, Otto K, et al. Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene. Oncogene 1999;18:6343-56.
13. An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999;154:113-8.
14. Knuutila S, Bjorkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998;152:1107-23.
15. Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999;93:4365-74.
16. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma Blood 1998;92:234-40.
17. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
18. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
19. Solenthaler M, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica 2002;87:1141-50.
20. Moller MB, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology 2002;41:322-30.
21. Pinyol M, Hernandez L, Martinez A, et al. INK4a/AKF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000;156:1987-96.
22. Ramirez RD, Herbert BS, Vaughan MB, et al. Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells. Oncogene 2003;22:433-44.
23. Jaffe ES, Harris NL, Stein H, Vardiman JW; WHO. Classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001.
24. Goff LK, Neat MJ, Crawley CR, et al. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol 2000;111:618-25.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
26. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
27. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002;2:9-15.
28. Tort F, Hernandez S, Bea S, et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 2002;100:4602-8.
29. Hernandez S, Bessa X, Bea S, et al. Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest 2001;81:465-73.
30. Matlasshewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
31. Hernandez-Boluda JC, Cervantes F, Colomer D, et al. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp Hematol 2003;31:204-10.
32. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:547-81.
33. Peto R, Pike MC. Conservatism of the approximation σ (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics 1973;29:579-84.
34. Cox D. Regression models and life tables. J R Stat Soc B 1972;34:187.
35. Beroud C, Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 2003;21:176-81.
36. Martin AC, Facchiano AM, Cuff AL, et al. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 2002;19:149-64.
37. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
38. Ridge SA, Dyer M, Greaves MF, Wiedemann LM. Lack of MDM2 amplification in human leukaemia. Br J Haematol 1994;86:407-9.
39. Korz C, Pscherer A, Benner A, et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 2002;99:4554-61.
40. De Vos S, Krug U, Hofmann WK, et al. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol 2003;12:35-43.
41. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of Grphase progression. Genes Dev 1999;13:1501-12.
42. Chen X, Oh SW, Zheng Z, Chen HW, Shin HH, Hou SX. Cyclin D-Cdk4 and cyclin E-Cdk2 regulate the Jak/STAT signal transduction pathway in Drosophila. Dev Cell 2003;4:179-90.
43. Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998;91:2977-84.
44. INKa and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 2000;14:1727-35.
45. He J, Allen JR, Collins VP, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-7.
46. Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M, Amornphimoltham P. Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol 2000;36:334-9.
47. Huang ZY, Baldwin RL, Hedrick NM, Gutmann DH. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. Oncogene 2002;21:1325-34.
48. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003;63:3459-63.
49. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003;4:181-9.
50. Morris M, Hepburn P, Wynford-Thomas D. Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function. Oncogene 2002;21:4277-88.
51. Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998;82:567-75.